Natera (NTRA) said Tuesday it is launching a clinical collaboration with Incyte (INCY) for a phase 2 trial to potentially treat colorectal cancer.

The trial will evaluate Incyte's INCA33890 in patients with stage 2/3 colorectal cancer who have completed surgery and chemotherapy.

After chemotherapy, patients will get longitudinal testing with Natera's Signatera for up to 12 months, and those who test Signatera MRD-positive may be eligible for enrollment and treatment in the trial, according to the statement.

Additionally, Natera will also supply trial-matching services to support patient identification for enrollment based on their Signatera MRD status and other criteria, it said.